2PIQ

androgen receptor LBD with small molecule

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.210 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history. 

Literature

A surface on the androgen receptor that allosterically regulates coactivator binding.

Estebanez-Perpina, E., Arnold, L.A., Arnold, A.A., Nguyen, P., Rodrigues, E.D., Mar, E., Bateman, R., Pallai, P., Shokat, K.M., Baxter, J.D., Guy, R.K., Webb, P., Fletterick, R.J.

(2007) Proc.Natl.Acad.Sci.Usa 104: 16074-16079

  • DOI: 10.1073/pnas.0708036104
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    • Current approaches to inhibit nuclear receptor (NR) activity target the hormone binding pocket but face limitations. We have proposed that inhibitors, which bind to nuclear receptor surfaces that mediate assembly of the receptor's binding partners, m ...

    Current approaches to inhibit nuclear receptor (NR) activity target the hormone binding pocket but face limitations. We have proposed that inhibitors, which bind to nuclear receptor surfaces that mediate assembly of the receptor's binding partners, might overcome some of these limitations. The androgen receptor (AR) plays a central role in prostate cancer, but conventional inhibitors lose effectiveness as cancer treatments because anti-androgen resistance usually develops. We conducted functional and x-ray screens to identify compounds that bind the AR surface and block binding of coactivators for AR activation function 2 (AF-2). Four compounds that block coactivator binding in solution with IC(50) approximately 50 microM and inhibit AF-2 activity in cells were detected: three nonsteroidal antiinflammatory drugs and the thyroid hormone 3,3',5-triiodothyroacetic acid. Although visualization of compounds at the AR surface reveals weak binding at AF-2, the most potent inhibitors bind preferentially to a previously unknown regulatory surface cleft termed binding function (BF)-3, which is a known target for mutations in prostate cancer and androgen insensitivity syndrome. X-ray structural analysis reveals that 3,3',5-triiodothyroacetic acid binding to BF-3 remodels the adjacent interaction site AF-2 to weaken coactivator binding. Mutation of residues that form BF-3 inhibits AR function and AR AF-2 activity. We propose that BF-3 is a previously unrecognized allosteric regulatory site needed for AR activity in vivo and a possible pharmaceutical target.

    Organizational Affiliation: 

    Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Androgen receptor
A
251Homo sapiensMutation(s): 0 
Gene Names: AR (DHTR, NR3C4)
Find proteins for P10275 (Homo sapiens)
Go to Gene View: AR
Go to UniProtKB:  P10275
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4
Download SDF File 
Download CCD File 
A
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
RB1
Query on RB1
Download SDF File 
Download CCD File 
A
3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
C16 H19 N5 O
QMAIQPBRCNEJAT-UHFFFAOYSA-N
 Ligand Interaction
DHT
Query on DHT
Download SDF File 
Download CCD File 
A
5-ALPHA-DIHYDROTESTOSTERONE
C19 H30 O2
NVKAWKQGWWIWPM-ABEVXSGRSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
DHTKi: 0.2 - 10 nM (100) BINDINGDB
DHTIC50: 0 nM (100) BINDINGDB
DHTEC50: 0.1 - 20 nM (100) BINDINGDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.210 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 56.640α = 90.00
b = 66.250β = 90.00
c = 71.870γ = 90.00
Software Package:
Software NamePurpose
CNSphasing
CNSrefinement
ELVESdata scaling
ELVESrefinement
ELVESdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots


View more in-depth experimental data

Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2007-09-25
    Type: Initial release
  • Version 1.1: 2011-07-13
    Type: Version format compliance
  • Version 1.2: 2017-10-18
    Type: Refinement description